Skip to main content

Advertisement

Table 3 Multiple Cox and logistic regression analyses for (A) overall survival, (B) progression free survival, and (C) chemotherapy response of clinicopathological parameters, ERα, TRAP1, and the ERα/TRAP1 expression pattern

From: Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

A) Overall survival
N = 208 Univariate Multivariate
   ERα TRAP1 Combination
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.44 (1.21-1.71) <0.001 1.40 (1.17-1.68) <0.001 1.42 (1.18-1.71) <0.001 1.50 (1.24-1.82) <0.001
Histology (non-serous vs serous) 1.05 (0.57-1.92) 0.874 1.20 (0.64-2.27) 0.555 1.22 0.65-2.29) 0.545 1.33 (0.70-2.52) 0.381
FIGO (IV vs III vs II) 1.96 (1.25-3.06) 0.003 1.39 (0.85-2.25) 0.187 1.38 (0.85-2.24) 0.188 1.39 (0.86-2.27) 0.176
Grade (3 vs 1,2) 1.74 (1.05-2.88) 0.032 0.98 (0.58-1.67) 0.951 1.34 (0.67-1.92) 0.631 0.96 (0.57-1.64) 0.893
Residual tumor (yes vs no) 2.35 (1.54-3.61) <0.001 1.87 (1.21-2.89) 0.005 1.79 (1.16-2.77) 0.009 1.80 (1.17-2.78) 0.008
Peritoneal Carcinomatosis (yes vs no) 3.01 (1.75-5.16) <0.001 2.75 (1.56-4.84) <0.001 2.45 (1.38-4.32) 0.002 2.68 (1.51-4.74) 0.001
ERα (1/2/3 vs 0) 0.56 (0.37-0.84) 0.005 0.51 (0.34-0.77) 0.002     
TRAP1 (3 vs 0/1/2) 0.63 (0.42-0.94) 0.025    0.65 (0.43-0.99) 0.044   
Combination ERα/TRAP1* 0.49 (0.32-0.75) 0.001      0.41 (0.27-0.64) <0.001
B) Progression free survival
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.21 (1.06-1.38) 0.041 1.14 (0.99-1.31) 0.056 1.15 (1.00-1.32) 0.055 1.17 (1.02-1.35) 0.027
Histology (non-serous vs serous) 0.91 (0.55-1.49) 0.701 1.23 (0.72-2.11) 0.453 1.25 (0.73-2.15) 0.416 1.25 (0.72-2.14) 0.428
FIGO (IV vs III vs II) 2.48 (1.69-3.62) <0.001 1.85 (1.22-2.79) 0.004 1.91 (1.26-2.89) 0.002 1.91 (1.26-2.89) 0.002
Grade (3 vs 1,2) 1.49 (1.03-2.17) 0.035 0.93 (0.62-1.39) 0.721 0.95 (0.64-1.41) 0.794 0.89 (0.59-1.33) 0.559
Residual tumor yes vs no) 1.99 (1.45-2.75) <0.001 1.56 (1.11-2.18) 0.010 1.55 (1.10-2.17) 0.011 1.56 (1.11-2.18) 0.010
Peritoneal Carcinomatosis (yes vs no) 2.96 (2.01-4.37) <0.001 2.98 (1.95-4.55) <0.001 2.92 (1.91-4.47) <0.001 3.00 (1.96-4.60) <0.001
ERα (1/2/3 vs 0) 0.84 (0.62-1.15) 0.279 0.80 (0.58-1.11) 0.185     
TRAP1 (3 vs 0/1/2) 0.87 (0.63-1.18) 0.367    0.87 (0.63-1.20) 0.398   
Combination ERα/TRAP1* 0.79 (0.56-1.12) 0.188      0.70 (0.48-1.02) 0.061
C) Chemotherapy response
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.33 (1.02-1.74) 0.036 1.42 (1.06-1.9) 0.019 1.43 (1.06-1.91) 0.019 1.57 (1.15-2.15) 0.005
Histology (non-serous vs serous) 0.74 (0.26-2.08) 0.567 0.92 (0.30-2.83) 0.889 0.93 (0.30-2.83) 0.893 0.88 (0.28-2.73) 0.824
FIGO (IV vs III vs II) 2.06 (1.02-4.15) 0.044 1.59 (0.73-3.49) 0.241 1.65 (0.76-3.61) 0.207 1.67 (0.75-3.72) 0.205
Grade (3 vs 1,2) 1.17 (0.56-2.44) 0.683 0.72 (0.32-1.64) 0.437 0.76 (0.33-1.72) 0.505 0.56 (0.23-1.33) 0.188
Residual tumor (yes vs no) 1.96 (1.01-3.80) 0.046 1.35 (0.67-2.75) 0.411 1.43 (0.71-2.91) 0.318 1.36 (0.66-2.81) 0.408
Peritoneal Carcinomatosis (yes vs no) 3.01 (1.32-6.85) 0.009 3.04 (1.25-7.36) 0.014 2.89 (1.19-7.01) 0.018 3.34 (1.34-8.36) 0.009
ERα (1/2/3 vs 0) 0.62 (0.33-1.17) 0.138 0.53 (0.26-1.06) 0.071     
TRAP1 (3 vs 0/1/2) 0.53 (0.28-1.00) 0.050    0.48 (0.24-0.96) 0.037   
Combination ERα/TRAP1* 0.38 (0.19-0.75) 0.005      0.24 (0.11-0.54) < 0.001
  1. *ERα and/or TRAP1 high vs ERα- and TRAP1 low.